BioSpace News Archive

Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101.

The dreaded needle-based appointments can be a thing of the past! Needle Buddies® is a syringe clip on that disguises the scary needle and syringe.

Dr. Andrea Remuzzi and his research team at The University of Bergamo have recently published a randomized-controlled MRI-based computational fluid dynamic study in the Journal of Vascular Access that revealed the impact of VasQ™ External Support on fistula morphology and flow.

Domain Therapeutics, today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

Data Bridge Market Research announces the release of the report on “Brain MRI Scan Market”. Brain MRI Scan report contains thorough description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis and porter’s five force analysis

An influential Behavioral health market report provides the segmentation of the global market on the basis of technology, application, product, and region.

According to Vision Research Reports, the global robotic prosthetics market was valued at USD 1,269.7 million in 2021 and it is expected to surpass around USD 2.99 billion by 2030, poised to grow at a CAGR of 9.98% from 2022 to 2030.

According to Vision Research Reports, the medical imaging phantoms market was surpassed at USD 147.8 million in 2021 and is expected to hit around USD 214.3 million by 2030, growing at a CAGR of 4.21% from 2022 to 2030.

SpineX Inc., a clinical stage bioelectric medtech company, today announced that the first patient has been enrolled in a pivotal trial evaluating the SCONE™ Device.

Bayer’s KERENDIA® (finerenone) was recognized by the American Diabetes Association (ADA) Standards of Medical Care in Diabetes—2022 with a new grade A recommendation* for improving cardiovascular (CV) outcomes and reducing the risk of chronic kidney disease (CKD) progression in patients with CKD associated with type 2 diabetes (T2D).